Literature DB >> 21281862

Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Cagri Yildirim-Toruner1, Betty Diamond.   

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with significant clinical heterogeneity. Recent advances in our understanding of the genetic, molecular, and cellular bases of autoimmune diseases and especially SLE have led to the application of novel and targeted treatments. Although many treatment modalities are effective in lupus-prone mice, the situation is more complex in human subjects. This article reviews the general approach to the therapy of SLE, focusing on current approved therapies and novel approaches that might be used in the future.
Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21281862      PMCID： PMC3053574          DOI： 10.1016/j.jaci.2010.12.1087

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


  75 in total

Review 1.  Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases.

Authors:  M Ballow
Journal:  J Allergy Clin Immunol       Date:  1997-08       Impact factor: 10.793

2.  Intravenous immunoglobulin treatment of lupus nephritis.

Authors:  Y Levy; Y Sherer; J George; J Rovensky; J Lukac; L Rauova; P Poprac; P Langevitz; F Fabbrizzi; Y Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2000-04       Impact factor: 5.532

3.  Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.

Authors:  J R Carneiro; E I Sato
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

Review 4.  Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

Authors:  A J Grillo-López; C A White; C Varns; D Shen; A Wei; A McClure; B K Dallaire
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

5.  Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus.

Authors:  G Sturfelt; P Roux-Lombard; F A Wollheim; J M Dayer
Journal:  Br J Rheumatol       Date:  1997-12

6.  Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

Authors:  L Llorente; Y Richaud-Patin; C García-Padilla; E Claret; J Jakez-Ocampo; M H Cardiel; J Alcocer-Varela; L Grangeot-Keros; D Alarcón-Segovia; J Wijdenes; P Galanaud; D Emilie
Journal:  Arthritis Rheum       Date:  2000-08

7.  A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response.

Authors:  Y Levy; Y Sherer; A Ahmed; P Langevitz; J George; F Fabbrizzi; J Terryberry; M Meissner; M Lorber; J B Peter; Y Shoenfeld
Journal:  Lupus       Date:  1999       Impact factor: 2.911

8.  Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus.

Authors:  Y B Park; S K Lee; D S Kim; J Lee; C H Lee; C H Song
Journal:  Clin Exp Rheumatol       Date:  1998 May-Jun       Impact factor: 4.473

9.  Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.

Authors:  N Auphan; J A DiDonato; C Rosette; A Helmberg; M Karin
Journal:  Science       Date:  1995-10-13       Impact factor: 47.728

10.  Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease.

Authors:  B N Becker; H Fuchs; R Hakim
Journal:  J Am Soc Nephrol       Date:  1995-04       Impact factor: 10.121
View more
  53 in total

Review 1.  Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention.

Authors:  M Wigren; J Nilsson; M J Kaplan
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

Review 2.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

Review 3.  BAFF and selection of autoreactive B cells.

Authors:  Zheng Liu; Anne Davidson
Journal:  Trends Immunol       Date:  2011-07-13       Impact factor: 16.687

4.  Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.

Authors:  Cristen B Chafin; Nicole L Regna; Sarah E Hammond; Christopher M Reilly
Journal:  Int Immunopharmacol       Date:  2013-10-09       Impact factor: 4.932

5.  Clinical trials in systemic lupus erythematosus: a status report on ongoing trials.

Authors:  Divya Gumber; Jisna Paul; Prabha Ranganathan
Journal:  Rheumatol Int       Date:  2014-04-22       Impact factor: 2.631

6.  A case of infantile systemic lupus erythematosus with severe lupus nephritis and EBV infection.

Authors:  Natsuko Kishi; Kenichi Suga; Sato Matsuura; Yukiko Kinoshita; Maki Urushihara; Shuji Kondo; Etsuko Kitano; Michiyo Hatanaka; Hajime Kitamura; Tetsuya Sato; Akihiko Maeda; Shoji Kagami
Journal:  CEN Case Rep       Date:  2013-02-14

Review 7.  Drugs in early clinical development for Systemic Lupus Erythematosus.

Authors:  Mariana Postal; Nailú Angélica Sinicato; Simone Appenzeller; Timothy B Niewold
Journal:  Expert Opin Investig Drugs       Date:  2016-04-07       Impact factor: 6.206

8.  C/EBP β mRNA expression is upregulated and positively correlated with the expression of TNIP1/TNFAIP3 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

Authors:  Tian Qian; Yan Chen; Xiaowei Shi; Jian Li; Fei Hao; Dongmei Zhang
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

Review 9.  Disease-modifying therapy of pediatric multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 10.  Systemic lupus erythematosus: a therapeutic challenge for the XXI century.

Authors:  Manuel F Ugarte-Gil; Graciela S Alarcón
Journal:  Clin Rheumatol       Date:  2014-02-28       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.